Eli Lilly skyrockets following positive Alzheimer's data
Positive results from phase II trial with drug against Alzheimer's disease, an area also occupying Novo Nordisk, cause Eli Lilly's share price to soar.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
US pharmaceutical firm Eli Lilly has a 14.2-percent higher indication in the premarket after the company's drug donanemab reached its primary endpoint in a phase II trial with patients against early symptomatic Alzheimer's disease, according to Bloomberg News.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
